Effects of Pueraria mirifica on vaginal artery vascularization in postmenopausal women with genitourinary syndrome of menopause

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20200624007

Enrollment

Registered

2020-06-24

Start date

2020-07-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genito urinary syndrome of menopause Pueraria mirifica

Interventions

Pueraria mirifica gel concentration 6% for vaginal application,Placebo gel

Placebo Comparator Drug,Placebo Comparator Drug

Pueraria mirifica gel,Placebo

Eligibility

Sex/Gender

Female

Age

50 Years to 70 Years

Inclusion criteria

Inclusion criteria: Postmenopausal home age 50-70 year with genitourinary syndrome of menopause

Exclusion criteria

Exclusion criteria: Women who had contraindication for hormonal use eg. hormonal dependence malignancy Sexual transmitted disease received hormonal treatment within 3 months before enrolled

Design outcomes

Primary

Measure	Time frame
Vaginal artery vascularization 15 minutes Ultrasound for vaginal artery pulsatile index	—

Secondary

Measure	Time frame
Vaginal maturation index 10min lactobacillus from pelvic examination	—

Countries

Thailand

Contacts

Public ContactPatsira Warinsiriruk

Ramathibodi hospital

puppapraew11@hotmail.com0866364424

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026